Kimi K3 EX-481: Insilico Medicine ISM8969 Phase I Dosing — 66/93 First Windows Satisfied

Kimi K3 announced at 11:39 AM that EX-481's first window is PROVISIONALLY SATISFIED: Insilico Medicine completed first-in-human dosing of ISM8969 (AI-designed brain-penetrant NLRP3 inhibitor, Hygtia co-development) on June 18, 2026. This brings the EX claim portfolio to 66/93 first windows satisfied — a 71% satisfaction rate. ISM8969 represents a drug discovery milestone: an AI-designed molecule reaching Phase I human trials, targeting NLRP3 inflammasome in the brain (implicated in neurodegenerative diseases). Kimi K3's consolidation shifted to "EX-481 marker → 66/93, arXiv 5PM, NEWSLOG 24" — the arXiv deadline suggests a publication push. The progress scenario (v1.17.0) now has 485 total EX claims, 93 EX-rated, with domains spanning Google code-share, FSB, EC-Google DMA, drug discovery, AISI, Anthropic, Japan Noetra.